ArticleBioMed research international2013
MHC universal cells survive in an allogeneic environment after incompatible transplantation.
Article in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Review
- Emerging Ethical Challenges in Manufacturing of Cell-Based Medicines.Advances in experimental medicine and biology · 2025Review
- Engineering immune-evasive allogeneic cellular immunotherapies.Nature reviews. Immunology · 2024Review
- Heart immunoengineering by lentiviral vector-mediated genetic modification during normothermicFrontiers in immunology · 2024Article
- CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice.Frontiers in genome editing · 2024Article
- Genetic Modification of Limbal Stem Cells to Decrease Allogeneic Immune Responses.Frontiers in immunology · 2021Article
- [Novel platelet pharming using human induced pluripotent stem cells].Bulletin de l'Academie nationale de medecine · 2020Review
- Generating low immunogenic pig pancreatic islet cell clusters for xenotransplantation.Journal of cellular and molecular medicine · 2020Article
- Paving the way towards universal treatment with allogenic T cells.Immunologic research · 2020Review
- Genetic Engineering of the Kidney to Permanently Silence MHC Transcripts DuringFrontiers in immunology · 2020Article
- Editorial: Transplantation of Marginal Organs-Immunological Aspects and Therapeutic Perspectives.Frontiers in immunology · 2020Article
- Low immunogenic endothelial cells endothelialize the Left Ventricular Assist Device.Scientific reports · 2019Article
- Silencing of HLA class I on primary human hepatocytes as a novel strategy for reduction in alloreactivity.Journal of cellular and molecular medicine · 2019Article
- Using genome editing to engineer universal platelets.Emerging topics in life sciences · 2019Article
- [The biocompatibility and immunogenicity study of decellularized tracheal matrix].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2018Article
- Generation of HLA-Universal iPSC-Derived Megakaryocytes and Platelets for Survival Under Refractoriness Conditions.Molecular medicine (Cambridge, Mass.) · 2016Article
- The European Hematology Association Roadmap for European Hematology Research: a consensus document.Haematologica · 2016Article
- HLA Class I Depleted hESC as a Source of Hypoimmunogenic Cells for Tissue Engineering Applications.Tissue engineering. Part A · 2015Article
- Downregulation of beta-microglobulin to diminish T-lymphocyte lysis of non-syngeneic cell sources of engineered heart tissue constructs.Biomedical materials (Bristol, England) · 2015Article
- Influence of immune responses in gene/stem cell therapies for muscular dystrophies.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell, tissue, and organ transplants are commonly performed for the treatment of different diseases. However, major histocompatibility complex (MHC) diversity often prevents complete donor-recipient matching, resulting in graft rejection. This study evaluates in a preclinical model the capacity of MHC class I-silenced cells to engraft and grow upon allogeneic transplantation. Short hairpin RNA targeting β2-microglobulin (RN_shβ2m) was delivered into fibroblasts derived from LEW/Ztm (RT1(l)) (RT1-A(l)) rats using a lentiviral-based vector. MHC class I (RT1-A-) expressing and -silenced cells were injected subcutaneously in LEW rats (RT1(l)) and MHC-congenic LEW.1W rats (RT1(u)), respectively. Cell engraftment and the status of the immune response were monitored for eight weeks after transplantation. In contrast to RT1-A-expressing cells, RT1-A-silenced fibroblasts became engrafted and were still detectable eight weeks after allogeneic transplantation. Plasma levels of proinflammatory cytokines IL-1 α , IL-1 β , IL-6, TNF- α , and IFN- γ were significantly higher in animals transplanted with RT1-A-expressing cells than in those receiving RT1-A-silenced cells. Furthermore, alloantigen-specific T-cell proliferation rates derived from rats receiving RT1-A-expressing cells were higher than those in rats transplanted with RT1-A-silenced cells. These data suggest that silencing MHC class I expression might overcome the histocompatibility barrier, potentially opening up new avenues in the field of cell transplantation and regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.